Windy City Media Group Frontpage News Home
CELEBRATING 28+ YEARS OF Lesbian Gay Bisexual and Transgender NEWS

Search Gay News Articles
Advanced Search
Gay News Sponsor Windy City Times 2014-04-16
Download Issue
  News Index       Archives   About WCMG    Publications    Bars & Clubs     Calendar   Videos   Advertisers    OUT! Guide    Classifieds   AIDS @ 32
 Local | National | World | Politics | Obits | Profiles | Views | Entertainment | Theater | Dance | Music | Film | Art | Books | TV/Gossip
 Travel | History | Marriage | Youth | Trans | Lesbian | Celebrations | Food | Nightlife | Sports | Health | Real Estate | Autos | Pets | Crime

Sugar & Spice: The Dawson Sugar & Spice: The Dawson
The Dawson has everything a restaurant needs to become an instant hot ...

Browse Gay News Index   Browse Gay News Archives
  Windy City Times

HIV drugs can prevent infection
by Bob Roehr
2010-12-01

facebook twitter del.icio.us stumble upon digg google +1 reddit email


HIV drugs can do a remarkable job of suppressing high viral loads to undetectable levels, but can they prevent that infection in the first place? Most people thought that they could in theory but there was no proof of that … until now.

Results from the Preexposure Prophylaxis Initiative ( iPrEx ) Trial found that drugs could reduce new infections by 43.8 percent in the high-risk men who have sex with men ( MSM ) and transgender persons in the study. It was published in the New England Journal of Medicine Nov. 23.

The $43.6-million trial enrolled 2,499 participants at 11 sites on four continents, including San Francisco and Boston in the United States. Despite the fact that MSM are much more likely to be infected with HIV—they are more than half of those infected in the US and in the broader epidemic of sub-Saharan Africa they are at least four times as likely as their heterosexual counterparts to be infected with the virus—this is the first large biochemical prevention study conducted in MSM.

Participants were randomized to receive once a day dose of either Truvada, a single pill containing the drugs emtricitabine and tenofovir, or placebo, essentially a sugar pill with no active ingredients. They also received counseling on HIV prevention at every meeting with the study team. The analysis was based on a median of 1.2 years on the drug.

Of the first 100 people to become infected with HIV, 64 were receiving placebo ( an annual infection rate of about 4 percent ) and 36 were on Truvada. The 43.8 percent rate of protection was no home run but within the same ballpark as the protection seen in other recent prevention trials; the vaginal microbicide trial of tenofovir gel in African women ( 39 percent ) and a vaccine trial in Thailand ( 31 percent ) .

Adherence

Digging deeper, the researchers found that adherence was a very important part of the equation. The men who took at least half of their doses had 50.2 percent fewer infections; those who took at least 90 percent of their medication had 72.8 percent fewer infections. Even the best drugs will not work if people don't take them as they should.

Robert Grant, M.D., is a researcher at the Gladstone Institute at the University of California San Francisco and the principle investigator of the study. He said they asked participants to report how often they took their pills, but because people often are "optimistic" in their recall, and sometimes report what they think researchers want to hear, the study also tested for levels of the drug in the blood of those who became infected.

"No drug was detected in 91 percent; the other 9 percent had detectible levels inside blood cells that were very low. The absence of drug in the blood is probably due to people not taking the drug, which could explain all of the infections that did occur" in that group, Grant said.

The association between adherence and the level of protection was similar to what was seen in the microbicides trial. People who most closely used the product as intended had the best results. Cutting corners gave HIV an opportunity that it quickly exploited.

Reactions

"The iPrEx study results are extreme important and provide strong evidence that PrEP [ preexposure prophylaxis ] can reduce HIV acquisition among a segment of society disproportionately affected by HIV/AIDS," said Anthony Fauci, MD, director of the NIH National Institute of Allergy and Infectious Diseases. It provided $27.8 million toward the study.

He emphasized that despite this good news, "correct and consistent use of condoms and a reduction in the number of sex partners still remain the most effective ways to protect yourself from HIV infection."

"This is great news," said Thomas J. Coates, Ph.D., a leading international HIV prevention researcher at the University of California Los Angeles David Geffen School of Medicine. "But if it would have been any lower, I would have been devastated."

University of Pittsburgh HIV prevention researcher Ronald Stall, Ph.D., called the results "very good news for gay men and other populations at high risk of HIV transmission." It also points to the continued need for better behavioral interventions to support adherence.

Money

Gilead Sciences manufactures Truvada and supported the iPrEx study by providing all of the drugs used. The company said it "will be working with the appropriate regulatory agencies to determine if data from this study warrant inclusion in the prescribing information for Truvada."

While doctors can prescribe drugs for "off label" use that the FDA has not approved, and some already prescribe Truvada for prevention, health insurance companies generally only reimburse for the use indicated on the label of the drug.

Adding a prevention indication to the drug label likely will require additional trials in MSM and other populations, particularly with regard to preventing vaginal transmission of HIV. Some of those studies already are underway.

"The big conundrum right now is what does it mean for practice?" Coates said the response was not sufficiently great to signal immediate widespread adoption of this approach as a prevention intervention, particularly given issues of cost.

The retail price of the drug in the United States is about $14,000 a year, while the NIH pharmacy purchases it for about $5,000 a year, Fauci said.

In developing countries, generic versions of Truvada can be purchased for as little as 40 cents a day, according to Grant. However, those are the same places where more than half of the people already infected with HIV, who meet guidelines to begin treatment, cannot do so because of the cost. It is unlikely that public health officials will devote scarce resources to Truvada when a condom will do the same job much more cheaply.

Furthermore, an international survey of more than 5,000 participants, to be released next week by the Global Forum on MSM & HIV, found that more than half of MSM worldwide do not have access to basic HIV prevention and treatment services. Adding PrEP to the mix will be a challenge.

The paper "Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men" is freely available from the New England Journal of Medicine at www.nejm.org/doi/full/10.1056/NEJMoa1011205.


facebook twitter del.icio.us stumble upon digg google +1 reddit email




Windy City Media Group does not approve or necessarily agree with the views posted below.
Please do not post letters to the editor here. Please also be civil in your dialogue.
If you need to be mean, just know that the longer you stay on this page, the more you help us.

Community forum to include first person cured of HIV 2014-04-10
Photographic fundraiser to support Ride For AIDS Chicago 2014-04-02
The AIDS Generation: Stories of Survival and Resilience 2014-04-01
VIEWS How media criminalizes HIV and how to change it 2014-04-01
President Obama names director, Office of Nat'l AIDS Policy 2014-03-24
AFC offers guide to HIV meds in Marketplace Plans 2014-03-20
AIDS Legal Council names new executive director 2014-03-18
Registration opens for Iowa HIV is Not a Crime June 2-5 2014-03-17
TPAN has new interim CEO 2014-03-17
Strub reflects on past and present AIDS activism 2014-03-13
DIFFA holds winter ball at Center on Halsted 2014-03-12
Sean Strub to make two Chicago appearances 2014-03-12
Arizona lawmaker comes out; mag gets HIV/AIDS patient lists 2014-03-12
NMAC, women of color fight to end HIV/AIDS epidemic 2014-03-10
Iowa court hears Lambda Legal case on HIV-based conviction 2014-03-10
National Women and Girls HIV/AIDS Awareness Day March 10 2014-03-07
Report: Treat HIV infection without Drugs? 2014-03-07
Genetically modified cells may be effective in treating HIV 2014-03-05
HIV/AIDS activist Sean Strub visiting March 12 2014-02-26
Chicago House unveiling 'The Tease' 2014-02-05
Wrapture' attendees enjoy cocktails, sneak preview 2014-01-28
TPAN refocuses, takes break from 'Chicago Takes Off' 2014-01-24
GMHC: Analysis shows budget cuts to critical AIDS programs 2014-01-22
BOOKS HIV/AIDS activist Sean Strub talks 'Body Counts' 2014-01-15
PositiveSingles.com sees membership rise in Chicago 2014-01-15
TPAN kickoff event Jan. 25 2014-01-14
President Obama appoints Birx to AIDS post 2014-01-10
TPAN to host kick-off event for the Ride for AIDS Chicago 2014-01-09
Colfax leaving White House AIDS office; lesbians have quintuplets 2013-12-25
HIV policy review in Defense Authorization Bill 2013-12-20
AIDS groups ask CDC to change reporting methods 2013-12-19
TPAN receives $100,000 from Alphawood Foundation 2013-12-12
Sweet Charity: AIDS Foundation of Chicago's World of Chocolate 2013-12-11
World of Chocolate commemorates World AIDS Day 2013-12-11
Dec. 15 brunch to mark Vital Bridges' 25th anniversary 2013-12-11
TPAN looks to future with new space 2013-12-10
Vida/SIDA celebrates 25 years with gala on World AIDS Day 2013-12-03
Fashion event marks World AIDS Day 2013-12-03
AIDS: Signs of progress, but cuts create worries 2013-12-03
'Barlesque 6' raises $57K 2013-12-03





Copyright © 2014 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
the online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 

 

 



 

Gay-owned B&B offers warmth in Rogers Park
 
Villa Loretta adds a touch of Hollywood to weddings
 
UIC delves into trans* healthcare policy with film
 
'This Is What It Feels Like' to be Armin van Buuren
 
Pam Grier talks 'Dining Out For Life,' comic conventions
 
Windy City Times Current DownloadNightspots Current DownloadQueercast Current Download
Windy City Media Group BlogsJoin Our Email List!Donate Now








  News Index       Archives   About WCMG    Publications    Bars & Clubs     Calendar   Videos   Advertisers    OUT! Guide    Classifieds   AIDS @ 32
 Local | National | World | Politics | Obits | Profiles | Views | Entertainment | Theater | Dance | Music | Film | Art | Books | TV/Gossip
 Travel | History | Marriage | Youth | Trans | Lesbian | Celebrations | Food | Nightlife | Sports | Health | Real Estate | Autos | Pets | Crime



About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Subscriptions      Distribution      Windy City Queercast     
Queercast Archives      Advertising  Rates      Deadlines      Advanced Search     
Press  Releases      Event Photos      Join WCMG  Email List      Email Blast     
Upcoming Events      Todays Events      Ongoing Events      Post an Event      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Blogs      Spotlight  Video      News Videos      Nightspots Videos      Entertainment Videos      Queercast Videos      Comedy Videos     
Classifieds      Real Estate      Place a  Classified     

Windy City Media Group produces Windy City Queercast, & publishes Windy City Times,
The Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community,
Nightspots, Out! Resource Guide, and Identity.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.